FM
SPRY icon

Foster & Motley’s ARS Pharmaceuticals SPRY Stock Holding History

Foster & Motley’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$118K Hold
14,780
– – 0.01% 404
2026
Q1 		$119K Hold
14,780
– – 0.01% 394
2025
Q4 		$172K Hold
14,780
– – 0.01% 385
2025
Q3 		$149K Hold
14,780
– – 0.01% 392
2025
Q2 		$258K Hold
14,780
– – 0.01% 360
2025
Q1 		$186K Buy
+14,780
New +$178K 0.01% 374

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Foster & Motley's SPRY Position: Q2 2026 in Review

Foster & Motley held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 14,780 shares worth $118K. The position accounts for 0.01% of the portfolio, ranked #404.

Foster & Motley first reported a position in SPRY in Q1 2025 and has held it in 6 quarters since. The position peaked at $258K in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Foster & Motley held 14,780 shares of ARS Pharmaceuticals worth $118K as of Q2 2026.
  • Foster & Motley left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up 0.01% of Foster & Motley's portfolio in Q2 2026, its #404 holding.
  • Foster & Motley first reported a position in ARS Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Foster & Motley's ARS Pharmaceuticals position peaked at $258K in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Foster & Motley's 13F filing for Q2 2026, filed 7 Aug 2026.